Jackson Creek Investment Advisors LLC Has $1.72 Million Stock Holdings in PTC Therapeutics, Inc. $PTCT

Jackson Creek Investment Advisors LLC lessened its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 38.4% during the 4th quarter, HoldingsChannel reports. The fund owned 22,603 shares of the biopharmaceutical company’s stock after selling 14,113 shares during the quarter. Jackson Creek Investment Advisors LLC’s holdings in PTC Therapeutics were worth $1,717,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in PTCT. Jefferies Financial Group Inc. acquired a new position in shares of PTC Therapeutics during the third quarter valued at $97,252,000. SG Americas Securities LLC lifted its stake in shares of PTC Therapeutics by 587.5% during the fourth quarter. SG Americas Securities LLC now owns 894,461 shares of the biopharmaceutical company’s stock valued at $67,943,000 after acquiring an additional 764,364 shares during the period. State Street Corp lifted its stake in shares of PTC Therapeutics by 22.1% during the second quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company’s stock valued at $146,347,000 after acquiring an additional 541,558 shares during the period. Vanguard Group Inc. lifted its stake in shares of PTC Therapeutics by 6.2% during the fourth quarter. Vanguard Group Inc. now owns 8,803,203 shares of the biopharmaceutical company’s stock valued at $668,691,000 after acquiring an additional 514,204 shares during the period. Finally, UBS Group AG lifted its stake in shares of PTC Therapeutics by 113.3% during the fourth quarter. UBS Group AG now owns 964,658 shares of the biopharmaceutical company’s stock valued at $73,275,000 after acquiring an additional 512,449 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PTCT shares. Barclays reaffirmed an “overweight” rating and set a $120.00 price target on shares of PTC Therapeutics in a research note on Monday, February 23rd. Royal Bank Of Canada upped their price target on PTC Therapeutics from $81.00 to $82.00 and gave the company a “sector perform” rating in a research note on Friday, May 8th. Raymond James Financial started coverage on PTC Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $108.00 price target on the stock. Weiss Ratings lowered PTC Therapeutics from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, TD Cowen raised PTC Therapeutics from a “hold” rating to a “buy” rating and upped their price target for the company from $75.00 to $90.00 in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, PTC Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $88.36.

PTC Therapeutics Trading Down 1.7%

NASDAQ:PTCT opened at $67.65 on Wednesday. PTC Therapeutics, Inc. has a 1-year low of $43.17 and a 1-year high of $87.50. The business’s 50-day moving average price is $69.17 and its two-hundred day moving average price is $72.42. The firm has a market capitalization of $5.61 billion, a price-to-earnings ratio of -29.03, a PEG ratio of 12.83 and a beta of 0.53.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.42. PTC Therapeutics had a negative return on equity of 362.45% and a negative net margin of 22.58%.The firm had revenue of $272.55 million for the quarter, compared to analyst estimates of $217.42 million. During the same quarter in the prior year, the firm posted $10.04 earnings per share. The company’s quarterly revenue was up 43.5% on a year-over-year basis. Sell-side analysts predict that PTC Therapeutics, Inc. will post 0.19 earnings per share for the current year.

Insider Transactions at PTC Therapeutics

In other PTC Therapeutics news, insider Neil Gregory Almstead sold 52,003 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $69.04, for a total value of $3,590,287.12. Following the transaction, the insider owned 60,137 shares of the company’s stock, valued at approximately $4,151,858.48. This represents a 46.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Lee Scott Golden sold 10,000 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $63.38, for a total value of $633,800.00. Following the completion of the transaction, the executive vice president directly owned 79,944 shares in the company, valued at $5,066,850.72. The trade was a 11.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 115,022 shares of company stock valued at $7,925,979. Corporate insiders own 5.50% of the company’s stock.

PTC Therapeutics Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.